JMP Securities Sees Clear Path To Approval Following Zogenix, Inc. (ZGNX) Resubmitted FINTEPLA NDA to FDA
Tweet Send to a Friend
JMP Securities analyst Jason Butler reiterated a Market Outperform rating and $69.00 price target on Zogenix, Inc. (NASDAQ: ZGNX).The analyst ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
